抗心律失常药合并非瓣膜性房颤患者口服抗凝药疗效与安全性比较
DOACs与VKAs相比不增加缺血性卒中风险(汇总HR 0.86, 95%CI 0.72-1.02),但降低大出血风险(汇总HR 0.84, 95%CI 0.78-0.92),阿哌沙班大出血风险降低更明显(汇总HR 0.71, 95%CI 0.63-0.81)。抗心律失常药类型无效应修饰作用。
要点
- DOACs不增加缺血性卒中风险,且大出血风险低于VKAs。
- 阿哌沙班大出血风险降低更显著(汇总HR 0.71)。
- 抗心律失常药类型(相互作用 vs 非相互作用)不影响上述结果。
核心结论
- 在合用抗心律失常药的非瓣膜性房颤患者中,DOACs与VKAs相比疗效相当但更安全。
主要发现
- DOACs与VKAs相比,缺血性卒中风险无显著差异(英国HR 0.90, 95%CI 0.61-1.32;魁北克HR 0.85, 95%CI 0.70-1.03;汇总HR 0.86, 95%CI 0.72-1.02; I2=0%)。
- DOACs与VKAs相比,大出血风险显著降低(英国HR 0.90, 95%CI 0.75-1.08;魁北克HR 0.83, 95%CI 0.76-0.91;汇总HR 0.84, 95%CI 0.78-0.92; I2=0%)。
- 阿哌沙班的大出血风险降低更明显(汇总HR 0.71, 95%CI 0.63-0.81; I2=74%)。
- 抗心律失常药类型(相互作用 vs 非相互作用)对结果无效应修饰作用。
临床怎么用
- 对于使用抗心律失常药的NVAF患者,可优先考虑DOACs而非VKAs以降低大出血风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIM: Our international cohort study assessed the comparative effectiveness and safety of direct oral anticoagulants (DOACs) and vitamin K antagonists (VKAs) among patients with non-valvular atrial fibrillation (NVAF) using antiarrhythmic drugs. METHODS: Using the United Kingdom's (UK's) Clinical Practice Research Datalink Aurum and Québec claims data, we assembled two study cohorts of patients with NVAF who initiated DOACs or VKAs while on antiarrhythmic drugs (2011-2020). Using an as-treated exposure definition, we assessed the risks of ischemic stroke and major bleeding associated with DOACs vs. VKAs. Cox proportional hazards models estimated hazard ratios (HRs) and 95% confidence intervals (CIs) after propensity score-based inverse-probability-of-treatment-weighting. Site-specific estimates were pooled together using random-effects models. Secondary analyses assessed effect measure modification by individual DOAC and type of antiarrhythmic drugs (interacting vs. non-interacting). RESULTS: The study cohort included 44 435 patients with NVAF initiating DOACs (n = 29 071) or VKAs (n = 15 364) while using antiarrhythmics. Compared to VKAs, DOACs were not associated with the risk of ischemic stroke (UK: HR, 0.90; 95% CI, 0.61-1.32/ Quebec: HR, 0.85; 95% CI, 0.70-1.03/ pooled: HR, 0.86; 95% CI 0.72-1.02; I2 = 0%) but with a decreased risk of major bleeding (UK: HR, 0.90; 95% CI, 0.75-1.08/Quebec: HR, 0.83; 95% CI, 0.76-0.91/pooled: HR 0.84; 95% CI 0.78-0.92; I2 = 0%); the latter was more pronounced with apixaban (pooled HR, 0.71; 95% CI, 0.63-0.81; I2 = 74%). There was no effect modification by type of antiarrhythmic drugs. CONCLUSIONS: DOACs were as effective but safer than VKAs among NVAF patients treated with antiarrhythmic drugs.
引用
- Meinert FM, Dimakos J, Cui Y, et al. Comparative effectiveness and safety of oral anticoagulants in patients with atrial fibrillation using antiarrhythmic drugs: An international cohort study. Br J Clin Pharmacol. 2025. PMID: 41316911. doi:10.1002/bcp.70391
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。